Working... Menu

Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02389920
Recruitment Status : Unknown
Verified March 2015 by Chul Won Jung, Samsung Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : March 17, 2015
Last Update Posted : March 17, 2015
Information provided by (Responsible Party):
Chul Won Jung, Samsung Medical Center

Brief Summary:
Describe the purpose of the study: This study aims to evaluate the improvement of Dasatinib-related adverse events and to evaluate the treatment effect and safety by measuring the genetic response of nilotinib with nilotinib 400mg BID for 12 months in Philadelphia chromosome-positive chronic myeloid leukemia patients intolerant to Dasatinib.

Condition or disease Intervention/treatment Phase
Leukemia, Chronic Myeloid Drug: Nilotinib Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : April 2015
Estimated Primary Completion Date : February 2018
Estimated Study Completion Date : December 2018

Arm Intervention/treatment
Experimental: Nilotinib
nilotinib 400mg BID for 12 months
Drug: Nilotinib

Primary Outcome Measures :
  1. The rate of improvement of Dasatinib-related adverse events [ Time Frame: at 3 months of nilotinib treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men and women ≥ 19 years old
  2. Performance status (ECOG) of 0, 1, or 2
  3. Chronic phase or accelerated phase chronic myeloid leukemia being treated for more than two weeks, switch to nilotinib.
  4. Appropriate target organ function defined as;

    - Bilirubin < 1.5 X ULN- Liver function test, AST (SGOT) and ALT (SGPT) < 2.5 X ULN- Creatinine < 1.5 X ULN- Serum amylase and lipase ≤ 1.5 X ULN- Alkaline phosphatase ≤ 2.5 X ULN (only if not related to tumor)

  5. Women of childbearing potential must have a negative pregnancy test (urine or serum) within 7 days prior to the start of study drug administration.
  6. Should have laboratory results as follows.

    - Potassium ≥ LLN- Magnesium ≥ LLN- Phosphorus ≥ LLN

  7. Voluntary, signed and dated informed consent prior to any study procedures being performed

Exclusion Criteria:

  1. Subjects with the T315I mutation
  2. Mutation known to be associated with low sensitivity to nilotinib(e.g., Y253H, E255K, E255V, F359V),
  3. Cardiac function abnormalities as follows are found.

    • FEVI < 45% or less than lower limit of normal of each center on ECG
    • QT interval cannot be measured on ECG
    • Complete right bundle branch block
    • Using a ventricular pacemaker
    • Congenital long QT syndrome or family history of long QT syndrome
    • Past or present clinically significant ventricular or atrial tachycardia
    • Clinically significant bradycardia at rest (< 50 beats/min)
    • Regardless of toxicity after Dasatinib intake, QTc > 480 msec (using the QTcF formula) at baseline ECG. If QTcF > 480 msec and electrolytes are not within the normal range, it is necessary to correct electrolytes and re-assess the patient's QTc. According to the result of QTc, the investigator makes a decision on the patient's enrollment.
    • Myocardial infarction within 12 months prior to the start of the study
    • Other clinically significant heart disease (e.g., unstable angina, congestive heart failure or uncontrolled hypertension)
  4. Cytopathologically confirmed central nervous system lumbar puncture (spinal tapping is not needed if it is not suspected of association with central nervous system)
  5. Severe or uncontrolled disease (e.g., uncontrolled diabetes mellitus, active or uncontrolled infection)
  6. History of significant congenital or acquired, bleeding disorder unrelated to cancer
  7. 25% or more of bone marrow has been treated with prior radiotherapy
  8. Not recovered from prior surgery or having a major surgery within 4 weeks from Day -1 of the study
  9. Treated with other investigational product within 30 days
  10. History of noncompliance with medical treatment or unable to voluntarily provide the written signed and dated informed consent
  11. Other primary cancer which is currently clinically significant and requires active treatment
  12. Currently treated with a strong CYP3A4 inhibitor (e.g., erythromycin, ketoconazole, itraconazol, voriconazol, clarithromycin, telithromycin, ritonavir, mibefradil), and the treatment cannot be stopped or switched to other drug before the start of study drug administration (For a complete list, refer to this link:
  13. Gastrointestinal dysfunction or gastrointestinal disease that may significantly change the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass)
  14. History of acute pancreatitis within the past 1 year or history of chronic pancreatitis
  15. Acute or chronic uncontrolled liver, pancreas or severe renal disease unrelated to the disease
  16. Currently treated with a drug which may prolong QT interval, and the treatment cannot be stopped or switched to other drug before the start of study drug administration (For a complete list of products which prolong QT interval, refer to
  17. Pregnant women, breast-feeding women

Layout table for additonal information
Responsible Party: Chul Won Jung, Samsung Medical Center Identifier: NCT02389920     History of Changes
Other Study ID Numbers: 2014-01-112
First Posted: March 17, 2015    Key Record Dates
Last Update Posted: March 17, 2015
Last Verified: March 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Philadelphia Chromosome
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Translocation, Genetic
Chromosome Aberrations
Pathologic Processes
Leukemia, Myeloid
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases